Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study.

Alfredo Papa*, Franco Scaldaferri, Marcello Covino, Antonio Tursi, Federica Furfaro, Giammarco Mocci, Loris Riccardo Lopetuso, Giovanni Maconi, Stefano Bibbò, Marcello Fiorani, Lucrezia Laterza, Irene Mignini, Daniele Napolitano, Laura Parisio, Marco Pizzoferrato, Giuseppe Privitera, Daniela Pugliese, Tommaso Schepis, Elisa Schiavoni, Carlo Romano SettanniLorenzo Maria Vetrone, Alessandro Armuzzi, Silvio Danese, Antonio Gasbarrini

*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has raised concerns in patients with inflammatory bowel disease (IBD), not only due to consequences of coronavirus disease 2019 itself but also as a possible cause of IBD relapse. The main objective of this study was to assess the role of SARS-CoV-2 in IBD clinical recurrence in a cohort of patients undergoing biological therapy. Second, we evaluated the difference in C-reactive protein (CRP) levels between the start and end of the follow-up period (ΔCRP) and the rate of biological therapy discontinuation. Patients with IBD positive for SARS-CoV-2 infection were compared with non-infected patients. IBD recurrence was defined as the need for intensification of current therapy. We enrolled 95 IBD patients with SARS-CoV-2 infection and 190 non-infected patients. During follow-up, 11 of 95 (11.6%) SARS-CoV-2-infected patients experienced disease recurrence compared to 21 of 190 (11.3%) in the control group (p = 0.894). Forty-six (48.4%) SARS-CoV-2-infected patients discontinued biological therapy versus seven (3.7%) in the control group (p < 0.01). In the multivariate analysis, biological agent discontinuation (p = 0.033) and ΔCRP (p = 0.017), but not SARS-CoV-2 infection (p = 0.298), were associated with IBD recurrence. SARS-CoV-2 infection was not associated with increased IBD recurrence rates in this cohort of patients treated with biological agents.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
Numero di pagine10
RivistaBiomedicines
Volume2022
DOI
Stato di pubblicazionePubblicato - 2022

Keywords

  • SARS-CoV-2
  • biological agents
  • inflammatory bowel disease

Fingerprint

Entra nei temi di ricerca di 'Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study.'. Insieme formano una fingerprint unica.

Cita questo